Holen Sie sich die Stockscreener-App
1.29
5.84%
-0.08
Handel nachbörslich:
1.35
0.06
+4.65%
Schlusskurs vom Vortag:
$1.37
Offen:
$1.29
24-Stunden-Volumen:
40,471
Relative Volume:
0.34
Marktkapitalisierung:
$4.02M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-9.32M
KGV:
-0.1015
EPS:
-12.7107
Netto-Cashflow:
$-7.30M
1W Leistung:
-14.56%
1M Leistung:
-10.42%
6M Leistung:
-39.72%
1J Leistung:
-61.38%
1-Tages-Spanne:
$1.26
$1.41
1-Wochen-Bereich:
$1.26
$1.68
52-Wochen-Spanne:
$0.952
$6.39
Tharimmune Inc Stock (THAR) Company Profile
Firmenname
Tharimmune Inc
Sektor
Branche
Telefon
302-743-2995
Adresse
1200 ROUTE 22 EAST, BRIDGEWATER
Vergleichen Sie THAR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
THAR
Tharimmune Inc
|
1.29 | 4.02M | 0 | -9.32M | -7.30M | -12.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Tharimmune Inc Aktie (THAR) Neueste Nachrichten
Tharimmune announces executive changes and new agreements - Investing.com Australia
Tharimmune announces executive changes and new agreements By Investing.com - Investing.com Nigeria
TharimmuneRandy Milby Resigns As CEO And Board Member - marketscreener.com
Tharimmune Holds Annual Meeting, Elects Directors - TipRanks
Tharimmune (THAR) Appoints Strategic Advisor to Enhance TH104 De - GuruFocus
Tharimmune Appoints Renowned Counter-Terrorism and Critical Infrastructure Expert James Gordon Liddy (CDR US Navy SEAL (Ret)) as Key Strategic Advisor Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback - Jonesboro Sun
FDA Clears Path for Tharimmune's Military Fentanyl Defense Drug as Navy SEAL Commander Joins Advisory Team - Stock Titan
Tharimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Tharimmune, Inc. SEC 10-Q Report - TradingView
Tharimmune appoints new executive chairman By Investing.com - Investing.com India
Tharimmune appoints new executive chairman - Investing.com Australia
Tharimmune IncAppoints Vincent Lopriore As Executive ChairmanSEC Filing - marketscreener.com
Tharimmune (THAR) Reports Promising Phase 1 Results for TH104 Bu - GuruFocus
Tharimmune (THAR) Advances TH104 as Key Medical Countermeasure | - GuruFocus
Tharimmune advances opioid prophylaxis drug TH104 - Investing.com
Tharimmune advances opioid prophylaxis drug TH104 By Investing.com - Investing.com South Africa
Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback - Weatherford Democrat
Tharimmune's New Drug Breakthrough: FDA Fast-Tracks Military Protection Against Weaponized Fentanyl - Stock Titan
Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences - Chronicle-Tribune
Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors - Bluefield Daily Telegraph
Stocks of Tharimmune Inc (THAR) are poised to climb above their peers - Sete News
Breakthrough Drug TH104 Clinical Data Selected for Two Premier Medical Conferences DDW and EASL - Stock Titan
Tharimmune Appoints Clay Kahler And Gary Stetz To Board - citybiz
Tharimmune (THAR) Expands Board with New Appointments | THAR Sto - GuruFocus
Tharimmune expands board with two new directors By Investing.com - Investing.com India
Tharimmune expands board with two new directors - Investing.com
Tharimmune Adds $500M Success Story Entrepreneur and Financial Expert to Board Leadership - Stock Titan
Tharimmune Inc’s latest rating changes from various analysts - knoxdaily.com
Tharimmune Inc (THAR) Stock: Uncovering 52-Week Market Trends - investchronicle.com
These Numbers Show Just How Powerful Tharimmune Inc (NASDAQ: THAR) Stock Is - Stocksregister
Tharimmune expands board, appoints new directors By Investing.com - Investing.com Nigeria
Tharimmune expands board, appoints new directors - Investing.com
FDA Nods to Tharimmune’s Countermeasure for Opioid Threats By Investing.com - Investing.com South Africa
FDA Nods to Tharimmune’s Countermeasure for Opioid Threats - Investing.com Australia
Now Is The Time To Build A Position In Tharimmune Inc (NASDAQ:THAR) - Marketing Sentinel
Observations on the Tharimmune Inc (NASDAQ:THAR) Growth Curve - uspostnews.com
Tharimmune (THAR) Advances TH104 with FDA Feedback on New Drug A - GuruFocus
Tharimmune (THAR) Advances TH104 with FDA Feedback on New Drug Application | THAR Stock News - GuruFocus
Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback - The Joplin Globe
FDA Clears Path for Tharimmune's Military-Grade Fentanyl Defense Drug: No New Trials Needed - Stock Titan
Tharimmune announces board retirements ahead of annual meeting - Investing.com
Tharimmune announces board retirements ahead of annual meeting By Investing.com - Investing.com South Africa
Press Release Distribution & PR Platform - ACCESS Newswire
Tharimmune (THAR) Expands Board with New Appointment | THAR Stoc - GuruFocus
Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors - Chronicle-Tribune
Healthcare Investment Expert Managing $150M Portfolio Strengthens Tharimmune's Strategic Leadership - Stock Titan
Tharimmune reports data on new biparatopic biologics - BioWorld MedTech
THAR stock touches 52-week low at $1.12 amid sharp annual decline By Investing.com - Investing.com South Africa
THAR stock touches 52-week low at $1.12 amid sharp annual decline - Investing.com Australia
Finanzdaten der Tharimmune Inc-Aktie (THAR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Tharimmune Inc-Aktie (THAR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| MILBY RANDY | CEO |
Dec 19 '24 |
Buy |
2.12 |
4,600 |
9,752 |
17,534 |
| Appajosyula Sireesh | Chief Operating Officer |
Nov 13 '24 |
Buy |
2.02 |
5,000 |
10,096 |
10,758 |
| MILBY RANDY | CEO |
Oct 08 '24 |
Buy |
2.09 |
2,500 |
5,221 |
12,934 |
| Appajosyula Sireesh | Chief Operating Officer |
Oct 08 '24 |
Buy |
1.93 |
5,000 |
9,650 |
16,364 |
1.91%
1.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):